MedTrace Logo

CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

NCT00643617 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 307

Last updated 2023-05-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.

Conditions

  • Prostate Cancer
  • Prostatic Cancer
  • Prostatic Neoplasms
  • Prostate Neoplasms
  • Cancer of the Prostate

Interventions

RADIATION

CyberKnife Stereotactic Radiosurgery - Low Risk

38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 2 mm around the prostate

RADIATION

CyberKnife Stereotactic Radiosurgery - Intermediate Risk

38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 5mm posterolaterally

Sponsors & Collaborators

  • Accuray Incorporated

    lead INDUSTRY

Principal Investigators

  • Donald B Fuller, MD · CyberKnife Centers at San Diego, CA

  • George Mardirossian, PhD · CyberKnife Centers of San Diego, CA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-22
Primary Completion
2022-04-07
Completion
2022-04-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00643617 on ClinicalTrials.gov